Download PDF
Case Studies > Immatics Builds on Genedata Biologics for Cell Therapy Innovation

Immatics Builds on Genedata Biologics for Cell Therapy Innovation

Technology Category
  • Application Infrastructure & Middleware - Data Visualization
  • Application Infrastructure & Middleware - Database Management & Storage
  • Platform as a Service (PaaS) - Data Management Platforms
Applicable Industries
  • Healthcare & Hospitals
  • Life Sciences
Applicable Functions
  • Product Research & Development
  • Quality Assurance
Use Cases
  • Condition Monitoring
  • Predictive Maintenance
  • Process Control & Optimization
Services
  • Data Science Services
  • System Integration
The Challenge
Immatics is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies to treat cancer patients with solid tumors. The company employs two innovative proprietary technologies, XPRESIDENT® and XCEPTOR®, to develop T cell receptor-based immunotherapies. The TCR-related R&D workflow at Immatics is very sophisticated, involving hundreds of individual steps and iterations to generate new molecules and cell lines, engineer and optimize the therapeutic modalities, and constantly test and monitor them to see if they are fit-for-purpose. Each step generates critically important data that needs to be captured, processed, analyzed, and made available to various R&D teams. The complex data stream includes all molecule, sequence, and sample details, assay, and analytics values, as well as decisions such as the CDR combinations to be used to engineer distinctive TCR bispecific molecules. This data must be integrated, stored, related, and interpreted in real time to support the day-to-day activities of the various Immatics’ R&D teams.
About The Customer
Immatics is a globally operating clinical-stage biopharmaceutical company that is developing novel T cell receptor (TCR) -based immunotherapies. The company focuses on the treatment of cancer patients with solid tumors. To develop T cell receptor-based immunotherapies, Immatics employs two innovative proprietary technologies. Immatics’ XPRESIDENT® technology is one of the largest mass spectrometry platforms in the world, encompassing numerous tumor sample spectra. This allows Immatics to identify the peptides unique to tumor tissue, representing potential novel cancer targets. Immatics’ XCEPTOR® technology is used to identify T cell receptors that bind the tumor-specific targets, isolate their binding regions, and further optimize them for even greater specificity and improved affinity. Protein engineering is then applied to design and produce TCRs with desired binding characteristics for use in two therapeutic approaches: autologous and allogeneic adoptive cell therapies and TCR-based bispecific molecules. The company’s proprietary pipeline currently includes seven product candidates in pre-clinical and clinical stages. Ten additional programs are developed with leading biopharmaceutical companies such as Bristol Myers Squibb, GlaxoSmithKline, Amgen, and Genmab.
The Solution
Immatics performed a comprehensive market assessment, based on their specific requirements, before choosing Genedata Biologics®. While the preference was for a commercial off-the-shelf (COTS) product to provide a maximum of built-in functionalities, facilitate deployment, and ensure future maintenance, a custom development project was also considered. During the deployment project, Genedata worked closely with Immatics to optimally set up the platform and configure Immatics-specific CGT workflows. With extensive domain knowledge and experience from working with both small and large cell and gene therapy companies, Genedata knows how to accelerate, simplify, and optimize specialized CGT processes directly with each customer. Genedata Biologics is now used productively for all proprietary and partnered R&D programs at Immatics, including bispecifics and adoptive cell therapies. As an integrated workflow platform, it enables efficient screening, engineering, production, and testing of TCRs and TCR-based molecules, as well as lentivirus production and cell line development. The system comprehensively tracks properties of each therapeutic candidate, including specificity, efficacy, safety, stability, manufacturability, and developability. It also provides the necessary scalability to support Immatics’ quickly growing R&D organization.
Operational Impact
  • Streamlined workflows, central access to all TCR-related R&D data, improved collaboration across various teams, more transparent decision-making
  • Significant efficiency gains and cost savings. Documenting day-to-day lab operations has been streamlined and simplified, and scientists can now focus more on exciting R&D projects and experimentation
  • Reduced manual errors and inconsistencies, which is an additional major benefit on top of the efficiency gains
Quantitative Benefit
  • Ongoing cost savings outweigh the investment of bringing in the Genedata platform
  • Decreased overall ongoing operating costs

Related Case Studies.

Contact us

Let's talk!

* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.